Retrospective Cohort Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 7, 2017; 23(13): 2355-2364
Published online Apr 7, 2017. doi: 10.3748/wjg.v23.i13.2355
Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b
Daisuke Endo, Kenichi Satoh, Noritomo Shimada, Atsushi Hokari, Yoshio Aizawa
Daisuke Endo, Kenichi Satoh, Atsushi Hokari, Yoshio Aizawa, Department of Gastroenterology and Hepatology, Internal Medicine of Jikei University Katsushika Medical Center, Tokyo 125-8506, Japan
Noritomo Shimada, Department of Gastroenterology and Hepatology Internal Medicine of Otakanomori Hospital, Chiba 277-0863, Japan
Author contributions: Aizawa Y designed the research; Endo D, Satoh K, Shimada N, Hokari A and Aizawa Y treated the patients and collected materials and clinical data; Endo D, Satoh K and Aizawa Y analyzed the data; and Endo D and Aizawa Y wrote the paper.
Institutional review board statement: The study was approved by the ethics committee of the Jikei University School of Medicine (Tokyo, Japan).
Informed consent statement: Informed consent was obtained from all the patients for inclusion in the study.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset are available from the corresponding author at enddai1209@yahoo.co.jp. No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Daisuke Endo, MD, Department of Gastroenterology and Hepatology, Internal Medicine of Jikei University Katsushika Medical Center, 6-41-2 Aoto, Katsushikaku, Tokyo 125-8506, Japan. enddai1209@yahoo.co.jp
Telephone: +81-33-60321111 Fax: +81-33-8389944
Received: December 28, 2016
Peer-review started: December 30, 2016
First decision: January 19, 2017
Revised: February 20, 2017
Accepted: March 15, 2017
Article in press: March 15, 2017
Published online: April 7, 2017
Processing time: 98 Days and 23.8 Hours
Abstract
AIM

To investigate the influence of interferon-free antivirus therapy on lipid profiles in chronic hepatitis C virus genotype 1b (HCV1b) infection.

METHODS

Interferon-free antiviral agents were used to treat 276 patients with chronic HCV1b infection, and changes in serum lipids of those who achieved sustained virologic response (SVR) were examined. The treatment regimen included 24 wk of daclatasvir plus asunaprevir (DCV + ASV) or 12 wk of sofosbuvir plus ledipasvir (SOF + LDV). SVR was achieved in 121 (85.8%) of 141 patients treated with DCV + ASV and 132 (97.8%) of 135 patients treated with SOF + LDV. In the two patient groups (DCV + ASV-SVR and SOF + LDV-SVR), serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides were measured at baseline during treatment and at 4 and 12 wk after treatment. Then, longitudinal changes in lipid profiles were analyzed.

RESULTS

Serum levels of TC, LDL-C, and HDL-C were significantly increased throughout the observation period in both the DCV + ASV-SVR and SOF + LDV-SVR groups. During antivirus treatment, the increases in TC and LDL-C were significantly greater in the SOF + LDV-SVR group than in the DCV + ASV-SVR group (P < 0.001). At 4 and 12 wk after the therapy, serum levels of TC and LDL-C were similar between the two groups and were significantly greater than those at baseline. Approximately 75%-80% of the increase in TC was derived from an increased LDL-C. In multiple regression analysis, the difference in therapy protocol (DCA + ASV or SOF + LDV) was an independent predictor that was significantly associated with the increase in TC and LDL-C at 4 wk of therapy.

CONCLUSION

Serum cholesterol significantly increased during SOF + LDV treatment. After treatment, HCV elimination was associated with a similar increase in cholesterol regardless of the therapy protocol.

Keywords: Chronic hepatitis C; Daclatasvir; Asunaprevir; Sofosbuvir; Ledipasvir; Total cholesterol; Low-density lipoprotein cholesterol

Core tip: Hepatitis C virus genotype 1b (HCV1b) infection is associated with a decrease in serum cholesterol. However, little is known about the changes in lipid metabolism caused by anti-HCV therapy. Changes in serum lipid profiles were examined during and after two types of interferon-free antiviral therapy for chronic HCV1b infection. Total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels increased post therapy regardless of the regimen. However, the change in cholesterol during the treatment markedly varied according to the therapy protocol. These findings indicated that each anti-HCV regimen had a unique influence on lipid profiles during treatment.